Identificación de usuariosPortal de Empleo I+D+i
 COMPARTIR OFERTA
Facebook  Twitter  LinkedIn 
Imprimir en blanco y negro

Ofertas de empleo


AVISO: Esta oferta no se encuentra activa.

Oferta de Trabajo  Código: 41837  

Puesto: Postdoctoral

Función: Dr Malu Martinez-Chantar lab is looking for a highly motivated and outstanding student to apply for the fellowship AECC postdoc in the Liver Disease lab in CIC bioGUNE
Empresa: Liver Disease CIC bioGUNE  
Referencia: Postdoc AECC Publicada el 17/11/2021 Publicada hasta el 10/12/2021
Tipo de Contrato: Beca Dedicación: Jornada completa  
Localidad: Derio Provincia: Bizkaia Disponibilidad para viajar: Si
Fecha de Incorporación: Febrero 2022 Fecha de Finalización: 5 años
Enlace URL: www.cicbiogune.es/people/mlmartinez

Nivel Académico
Doctor  

Áreas tecnológicas
A- Biociencias
B- Ciencias de la Salud

Idiomas
Idioma: Inglés Nivel Lectura: Alto Nivel Escrito: Alto Nivel Conversación: Alto

Experiencia
PhD Fellow
in Dr Malu Martinez-Chantar Lab (Liver Disease Lab) at CIC bioGUNE, Vizcaya



Dr Malu Martinez-Chantar lab is looking for a highly motivated and outstanding student to apply for the fellowship AECC postdoc in the Liver Disease lab in CIC bioGUNE


Scientific-technical training capacity of the research team
Dr Malu Martinez-Chantar is part of Ciberehd ISCIII (Centro de Investigacion Médica en Red de Enfermedades Hepáticas y Digestivas), which the main objective is to promote excellence research into liver and digestive diseases in an international context.Thus, the student will have the possibility to enroll the exchange program belong to Ciber for Liver Disease for learning new techniques, clinical approaches and translational research. Also, the involvement of the PI in the select European group of Woman in Hepatology will increase the possibilities of collaboration with internationally recognized laboratories. Finally, the network of the PI not only in the area of hepatology but also in molecular and cellular biology has been intensified through an extensive participation in different national and international networks like Hepamet Registry, MetaboCancer Excellence Network and different European COST actions PROTEOSTASIS, TRANSAUTOPHAGY and MITOEAGLE.
Based on available information and our preliminary data, we propose that impaired magnesium homeostasis is involved in determining several traits of malignancy that are characteristic of HCC, which accounts for the poor prognosis of this cancer.
The general objective of this project is to elucidate the role of the magnesium transporter "cyclin and CBS domain divalent metal cation transport mediator 1" (gene symbol CNNM1) in HCC biology and explore the usefulness of modulating magnesium content in cancer cells by pharmacological manipulation as a novel strategy to inhibit HCC development.